WWW.JNEUROSCI.ORG
-
The Journal of Neuroscience
 QUICK SEARCH:   [advanced]


     
-


HOME
  |  
SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (42)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stiedl, O.
Right arrow Articles by Ögren, S. O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stiedl, O.
Right arrow Articles by Ögren, S. O.

 Previous Article  |  Next Article 

The Journal of Neuroscience, November 15, 2000, 20(22):8515-8527

Involvement of the 5-HT1A Receptors in Classical Fear Conditioning in C57BL/6J Mice

Oliver Stiedl1, Ilga Misane2, Joachim Spiess1, and Sven Ove Ögren2

1 Department of Molecular Neuroendocrinology, Max Planck Institute for Experimental Medicine, D-37075 Goettingen, Germany, and 2 Karolinska Institutet, Division of Behavioral Neuroscience, Department of Neuroscience, SE-171 77 Stockholm, Sweden

The present study examined the involvement of the 5-HT1A receptors in classical fear conditioning using the 5-HT1A agonist 8-hydroxy-2-(di-n-propyloamino)tetralin hydrobromide (8-OH-DPAT) and the selective "silent" 5-HT1A receptor antagonist (N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridinyl)cyclo-hexane carboxamide trihydrochloride (WAY 100635). The drugs were administered both subcutaneously and bilaterally into the dorsal hippocampus of male C57BL/6J mice. The training was performed in a single trial in which a tone was followed by a footshock. The retention of context- and tone-dependent fear was examined in separate tests conducted either 1 or 24 hr after training. Subcutaneous 8-OH-DPAT (0.1-1.0 mg/kg), when injected before but not after training, caused a dose-dependent impairment of contextual fear in both 1 and 24 hr tests, whereas tone-dependent fear was less affected. Pretraining intrahippocampal injections of 5.0 µg but not 1.0 µg 8-OH-DPAT caused a severe deficit in contextual fear when tested 24 hr after training. When injected both subcutaneously and intrahippocampally, 8-OH-DPAT induced the 5-HT syndrome, indicative of postsynaptic 5-HT1A receptor activation at the dose ranges that impaired fear conditioning. However, the behavioral changes induced by 8-OH-DPAT at the time of training could not account for inhibitory effects of 8-OH-DPAT on fear conditioning. Neither subcutaneous (0.03 mg/kg) nor intrahippocampal (0.5 µg per mouse) WAY 100635 altered context- or tone-dependent fear. However, subcutaneous WAY 100635 blocked both the 5-HT syndrome and the impairment of fear conditioning induced by subcutaneous or intrahippocampal 8-OH-DPAT. In contrast, intrahippocampal WAY 100635 blocked the impairment caused by intrahippocampal but not subcutaneous 8-OH-DPAT, indicating the involvement of extrahippocampal 5-HT1A receptors in fear conditioning. It is concluded that the deficits in fear conditioning induced by 8-OH-DPAT are a result of postsynaptic 5-HT1A receptor activation that interferes with learning processes operating at acquisition but not consolidation. Furthermore, the dorsohippocampal 5-HT1A receptors play an important but not exclusive role in the limbic circuitry subserving contextual fear conditioning.

Key words: serotonin; presynaptic and postsynaptic 5-HT1A receptors; dorsal hippocampus; fear conditioning; 8-OH-DPAT; WAY 100635


Copyright © 2000 Society for Neuroscience  0270-6474/00/20228515-13$05.00/0


This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
A. Karlen, T. E. Karlsson, A. Mattsson, K. Lundstromer, S. Codeluppi, T. M. Pham, C. M. Backman, S. O. Ogren, E. Aberg, A. F. Hoffman, et al.
Nogo receptor 1 regulates formation of lasting memories
PNAS, December 1, 2009; 106(48): 20476 - 20481.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
W. D. Hirst, T. H. Andree, S. Aschmies, W. E. Childers, T. A. Comery, L. A. Dawson, M. Day, I. B. Feingold, S. M. Grauer, B. L. Harrison, et al.
Correlating Efficacy in Rodent Cognition Models with in Vivo 5-Hydroxytryptamine1A Receptor Occupancy by a Novel Antagonist, (R)-N-(2-Methyl-(4-indolyl-1-piperazinyl)ethyl)-N-(2-pyridinyl)-cyclohexane Carboxamide (WAY-101405)
J. Pharmacol. Exp. Ther., April 1, 2008; 325(1): 134 - 145.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
N. Madjid, E. E. Tottie, M. Luttgen, B. Meister, J. Sandin, A. Kuzmin, O. Stiedl, and S. O. Ogren
5-Hydroxytryptamine 1A Receptor Blockade Facilitates Aversive Learning in Mice: Interactions with Cholinergic and Glutamatergic Mechanisms
J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 581 - 591.
[Abstract] [Full Text] [PDF]



-

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help

-
Copyright 2010 by Society for Neuroscience ONLINE ISSN: 1529-2401
-